ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 623

Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus

Ben Parker1, Awal Zaki2, M. Yvonne Alexander3 and Ian N. Bruce4, 1Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, 2Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 3Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 4Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, inflammation and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of clinical and subclinical cardiovascular disease (CVD) including endothelial dysfunction, in part due to systemic inflammatory disease activity. Endothelial microparticles (EMPs) are membrane-bound subcellular particles produced by endothelial cells in response to a variety of activation triggers, including inflammatory cytokines and classic CVD risk factors. EMPs reflect endothelial damage and may correlate with measures of endothelial function, such as flow-mediated dilatation (FMD) of the brachial artery.  EMPs may therefore serve as a biomarker for endothelial dysfunction in SLE. We aimed to: 1) compare EMP levels and FMD in patients with active SLE compared to controls; 2) assess change over time in EMP and FMD following improved disease control and 3) assess the correlation between EMPs and FMD.

Methods: Patients with active SLE (≥4 ACR criteria) were recruited and assessed at baseline and 4 months after a change in therapy. Disease activity (BILAG 2004 and SLEDAI 2K) and clinical features were recorded at each visit. Healthy age-matched controls were assessed once. FMD (%) of the brachial artery was measured using 2D ultrasound and automated edge-tracking software. EMPs were quantified (number/ml) using flow cytometry after incubating platelet-poor-plasma with the cell surface markers CD31, CD42b and Annexin-V. Events positive for annexin-V and CD31, and negative for CD42b, were classified as EMPs. Continuous data were compared using Mann-Whitney test, and Spearman’s Rank was used to correlate EMP levels with %FMD.

Results: 27 patients with SLE (mean (SD) age 41.5 (14.1) yrs) and 22 controls (mean age (SD) 38.5 (9.3) yrs) underwent assessment of endothelial function. In SLE patients the mean (SD) SLEDAI-2K and total BILAG scores were 8.2 (5.5) and  16.9 (10.6) respectively. Endothelial-dependent FMD was significantly reduced in the SLE group compared to controls at baseline (median (IQR) FMD 1.63% (-1.22, 5.32) vs. 5.40% (3.02, 8.57); p = 0.05). EMPs (n/ml) were significantly elevated in the SLE cohort compared to controls at baseline (median (IQR) 157,548/ml (59,906, 272,643) vs. 41,025 (30,179, 98,082); p = 0.003). In patients with paired results, disease activity significantly improved 4 months after a change in therapy (SLEDAI-2K 3.8 (3.4); BILAG 2004 score 6.9 (5.4) (p= 0.001 and 0.001 vs. baseline respectively). The median (IQR) FMD improved over time (0.33% (-2.31, 4.1) vs. 3.19% (0.98, 5.09); p = 0.1), as did median (IQR) EMP levels (166,982/ml (59906, 278,775 vs. 55655 (29475, 188,659; p = 0.02). In the whole cohort, EMPs demonstrated a significant negative correlation with %FMD (correlation coefficient -0.42; p =0.008). In SLE patients with paired data the correlation coefficient was -0.51 (p = 0.005).

Conclusion: Endothelial function is significantly impaired and EMPs are significantly elevated in young patients with active SLE compared to healthy controls. Both EMPs and FMD improve over time, following a reduction in disease activity.  EMPs also correlate with FMD, and may serve as a useful biomarker of endothelial damage/dysfunction and CVD risk in SLE.


Disclosure:

B. Parker,
None;

A. Zaki,
None;

M. Y. Alexander,
None;

I. N. Bruce,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelial-microparticles-as-a-biomarker-for-endothelial-dysfunction-in-active-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies